Hoffmann-la Roche Inc.

Siena Biotech S.p.a.

F. Hoffmann-la Roche Ag

Harald Mauser

Hans Hilpert

David Banner

Mark Rogers-Evans

Thomas Johannes Woltering

Wolfgang Wostl

Wolfgang Guba

Alexander Mayweg

Robert Narquizian

Patrizio Mattei

Daniel Hunziker

Wolfgang Haap

Holger Kuehne

Eoin Power

Bernd Kuhn

Uwe Grether

Jean-Marc Plancher

Roland Humm

Emanuele Gabellieri

Emmanuel Pinard

Simona Maria Ceccarelli

Lisha Wang

Jerome Hert

Christoph Ullmer

Didier Rombach

Guozhi Tang

Marco Prunotto

Alexander V Mayweg

Massimiliano Travagli

Matteo Andreini

Andrew William Thomas

Benoit Hornsperger

Hans Peter Wessel

Fabienne Ricklin

Guido Hartmann

Jérôme Hert

Ruben Alvarez Sanchez

Rudolf E Minder

Rubén Alvarez Sánchez

Michela Valacchi

Peter Hartman

The invention provides novel compounds having the general formula (I) wherein R, Y, A, W, R, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds.

Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors

Bicyclic derivatives

Compounds having the general formula (I) wherein R, R, Y and W are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.

Diazaspirocycloalkane and azaspirocycloalkane

The invention relates to a compound of formula (I) wherein A, Aand Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Piperidine derivatives

The invention provides novel compounds having the general formula (I) wherein R, R, Y and W are as described herein, compositions including the compounds and methods of using the compounds.

The present invention relates to 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

1,4 oxazines as BACE1 and/or BACE2 inhibitors

This invention relates to compounds of the formula wherein Rto Rare as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.

1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds

The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

1,4-oxazepines as BACE1 and/or BACE2 inhibitors

This invention relates to compounds of the formula wherein A, B and Rto Rare as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds

The invention relates to a compound of formula (I) wherein Ato Aand Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used, for example, as inhibitors of the cysteine protease cathepsin.

Pyrrolidine derivatives

This invention relates to dihydropyrimidinones of the formula wherein X and Rto Rare as defined in the description, as well as pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the treatment or prevention of diseases such as diabetes.

Dihydropyrimidinones

The present invention relates to 2-Amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

2-amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides

The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines

The invention relates to a compound of formula (I) wherein A, R-Rare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Proline derivatives

The invention is concerned with the novel sulfonamide derivatives of formula (I) wherein A, Rto R, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit chymase and can be used as medicaments.

Sulfonamide derivatives

Growing community of inventors

Riehen, Switzerland

Harald Mauser